Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

27 Nov 2015
Change (% chg)

-0.75kr (-1.11%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for MVIRb.ST


Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)


Beta: 1.55
Market Cap(Mil.): kr1,766.10
Shares Outstanding(Mil.): 26.36
Dividend: --
Yield (%): --


  MVIRb.ST Industry Sector
P/E (TTM): 7.59 40.04 34.31
EPS (TTM): 8.83 -- --
ROI: 15.87 -1.06 14.77
ROE: 16.06 1.35 15.97
Search Stocks

BRIEF-Medivir swings to a Q3 loss

* Q3 loss after tax was sek -10.5 million (373.7 m) Source text for Eikon: Further company coverage: (Stockholm Newsroom)

20 Nov 2015

BRIEF-Medivir says royalties for Olysio in q3 amounted to 57 msek

* Says global third quarter net sales of Olysio (simeprevir)amounted to 79 MUSD, of which 26 MUSD were sales in the USA.

13 Oct 2015

BRIEF-Healthinvest Partners increases Medivir stake to 5.1 pct

* Healthinvest Partners AB increases holding to 5.1 percent of shares, a FSA filing shows Further company coverage: (Stockholm Newsroom)

08 Sep 2015

BRIEF-Medivir Q2 pretax profit below forecast

* Medivir Q2 net turnover totalled SEK 245.8 million (564.0 m) vs 263 million seen in Reuters poll

20 Aug 2015

BRIEF-Medivir starts clinical trial for treatment of hepatitis C

* Medivir announces start of a phase i clinical trial of the nucleotide polymerase inhibitor al-704 for treatment of hepatitis c

29 Jul 2015

BRIEF-Medivir Q2 sales of Olysio 264 mln USD

* Medivir says global q2 net sales of olysio (simeprevir) amounted to 264 musd, of which 50 musd were sales in usa

14 Jul 2015

BRIEF-Medivir announces cancer project from in-house nucleotide platform

* Medivir announces the first cancer project derived from its in-house nucleotide platform Source text for Eikon: Further company coverage:

30 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
Provider : Wright Reports
Provider : Thomson Reuters StreetEvents
Provider : GlobalData
Provider : Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks